Rapid Solutions for Point-of-Care Diagnostics Provided Worldwide

A range of rapid diagnostic tests used for the detection of infectious diseases offers fast and cost-effective clinical solutions for point-of-care diagnostic testing.

The QuickVue range includes qualitative detection of influenza type A and type B antigens, a dipstick immunoassay for acute respiratory syncytial virus (RSV) infections, and a one-step human chorionic gonadotropin (hCG) test, as well as quick and simple tests for Helicobacter pylori, Chlamydia, and Streptococcus group A infections.

BioMerieux (Marcy l'Etoile, France) is now supplying the QuickVue range of rapid diagnostic tests worldwide, as part of a global alliance with Quidel Corp. (San Diego, CA, USA) for the development and distribution of rapid clinical diagnostic solutions. Many new tests are in the development pipeline.

The long-term global alliance between Quidel and bioMérieux was originally formed in 2008. The two companies planned to codevelop new rapid tests using Quidel's rapid test development capability and bioMérieux's expertise in immunochemistry and wide-ranging library of biologics, including antibodies and antigens.

BioMerieux provides diagnostic solutions (reagents, instruments, software) that determine the source of disease and contamination. Its products are used for diagnosing infectious diseases, for providing results for cancer screening and monitoring, and cardiovascular emergencies.

Quidel develops rapid diagnostic tests that allow for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care, and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit.

Related Links:

bioMerieux
Quidel